Date of publication: January 16,
2006
Source:
http://gmoinfo.jrc.it/gmp_browse_geninf.asp
Notification number:
B/SE/05/9900
Member State: Sweden
Date of Acknowledgement: 23/12/2005
Title of the Project:
Application for the deliberate release of oilseed rape lines
genetically modified for increased oil content in the seed - A.
Proposed period of release From:01/01/2006
To:31/12/2010
Name of the Institute(s) or Company(ies): Plant
Science Sweden AB;
3. Is the same GMPt release planned elsewhere in the
Community?
No
4 - Has the same GMPt been notified elsewhere by the same
notifier?
No
Genetically
modified plant
1. Complete name of the
recipient or parental plant(s)
|
Common Name
|
Family Name
|
Genus |
Species
|
Subspecies
|
Cultivar/breeding line
|
| spring
oilseed rape |
brassicaceae |
brassica |
brassica napus |
napus
(syn. oleifera) |
Westar
|
2. Description of the traits and characteristics which have
been introduced or modified, including marker genes and previous
modifications:
Genes involved in regulating the accumulation of seed storage
compounds have been introduced into spring oilseed rape in order
to increase the level of total oil in the seed. The neomycin
phosphotransferase II gene or the acetohydroxy acid synthase
gene (ahas) have been used as selectable marker genes to
identify transgenic cells in tissue culture.
Genetic
modification
3. Type of genetic
modification:
Insertion;
4. In case of insertion of genetic material, give the source
and intended function of each constituent fragment of the region
to be inserted:
The genes of interest are lipid metabolic enzyme 1, lipid
metabolic enzyme 3 and a DNA binding protein, all from
Arabidopsis thaliana. The genes are used in two combinations:
lipid metabolic enzyme 3 combined with each of the other two.
These genes of interest are regulated by promoters of genes for
seed storage proteins from Vicia faba: the usp–promoter or the
legumin B4 promoter. Alternatively a promoter from a
constitutively expressed gene from Pisum sativum is used.
The terminators used are:
- the terminators of the octopine synthase gene and nopaline
synthase gene from Agrobacterium tumefaciens;
- the terminator of the small subunit of the
ribulose-1,5-bisphosphate carboxylase gene from Pisum sativum;
- the terminator of the 35S gene from the Cauliflower mosaic
virus;
- the terminator of the legumin B3 gene from Vicia faba.
As selectable marker genes have been used:
- the neomycin phosphotransferease II gene (nptII) flanked by
the nopaline synthase promoter and terminator from Agrobacterium
tumefaciens,
or
- the acetohydroxy acid synthase gene (ahas) flanked by the
shortened triosephosphate transporter promoter (both from A.
thaliana) and the terminator region of the nopaline synthase
gene from A. tumefaciens.
6. Brief description of the method used for the genetic
modification:
A standard Agrobacterium tumefaciens based transformation
system was used for transformation of spring oilseed rape cv.
Westar according to Molony et al. (1989) and Hoekema (1983).
7. If the recipient or parental plant is a forest tree
species, describe ways and extent of dissemination and specific
factors affecting dissemination:
Not applicable.
Experimental
Release
1. Purpose of the release:
Evaluation of trait performance under field conditions and
selection of lines for further testing and analysis of the
trait.
2. Geographical location of the site:
Municipalities of Eslöv, Svalöv, Klippan and Vara.
3. Size of the site (m2):
Total Area will not exceed 150000 m2 (15 ha).
4. Relevant data regarding previous releases carried out with
the same GM-plant, if any, specifically related to the potential
environmental and human health impacts from the release:
The genes of interest have previously, as single gene
constructs, been grown in field releases in Sweden 2005
(B/SE/04/8095). No specific or general impact on the environment
or human health could be documented.
Environmental
Impact and Risk Management
Summary of the potential
environmental impact from the release of the GMPts:
The genetically modified oilseed rape lines show a modified
level of the inherent seed component oil. No difference
regarding persistence in agricultural habitats or invasiveness
in natural habitats compared to conventional spring oilseed rape
is expected. Nor is it expected that a selective advantage or
disadvantage is conferred to the GM lines via the introduced
trait. Due to the measures to be taken during the release
(distance to or absence of cultivated and wild relatives) the
potential for permanent gene transfer will be virtually
excluded. Interactions of the GM oilseed rape lines with
non-target species and resulting effects will be comparable to
those of conventional oilseed rape varieties. The potential of
elevated levels of the seed component oil resulting in any
effects on animal health from contact or consumption is
considered negligible. Measures in place under current field
trials in relation to handling, harvest, storing, transport or
disposition will further minimize the probability of any
negative effects on health or environment. No effects are
expected on biogeochemical processes from the predicted trait.
The GM oilseed rape lines will be cultivated under conventional
agricultural practices.
Brief description of any measures taken for the management of
risks:
The distance from the nearest cultivation of oilseed rape
plants will be at least 500 m. A 6m-wide protective border
containing unmodified male-sterile rape will surround
experimental areas. Sowing and harvesting machinery will be
cleaned on site to prevent the dispersal of GM seed. Harvested
seed material will be transported from the site in closed and
labeled containers to the laboratories for analyses. Remaining
seed will be inactivated. Vegetative plant material will be
chopped and worked into the soil. The area will be controlled
for volunteers for a period of 4 consecutive years. During the
release period the Field Manager and trained personnel will
monitor the trial site at defined intervals.
Summary of foreseen field trial studies focused to gain new
data on environmental and human health impact from the release:
Not applicable.
Final report
-
European
Commission administrative information
Consent given by the Competent
Authority: Not Known |
